Aptose Biosciences APTO
Jump To Section
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Business overview of Aptose Biosciences (APTO)
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.
Key Insights
Critical company metrics and information
Latest Closing Price
$3.17Market Cap
$6.79 MillionPrice-Earnings Ratio
-0.01Total Outstanding Shares
2.14 Million SharesTotal Employees
36Dividend
No dividendIPO Date
July 30, 1992SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQType
Common StockHeadquarters
66 wellington street west, suite 5300, Toronto, A6, M5K 1E6Homepage
https://www.aptose.com
Historical Stock Splits
If you bought 5,400 shares of APTO before October 6, 2014, you'd have 1 share today.
Execution Date | Split Amount |
---|---|
February 26, 2025 | 1-for-30 (Reverse Split) |
June 6, 2023 | 1-for-15 (Reverse Split) |
October 6, 2014 | 1-for-12 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities | $27.46 Million |
Net Cash Flow From Operating Activities, Continuing | $-37.18 Million |
Net Cash Flow From Operating Activities | $-37.18 Million |
Net Cash Flow From Financing Activities, Continuing | $27.46 Million |
Net Cash Flow | $-7.39 Million |
Net Cash Flow From Investing Activities, Continuing | $2.32 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Operating Expenses | $36.20 Million |
Net Income/Loss Attributable To Parent | $-35.80 Million |
Diluted Average Shares | $48.81 Million |
Income/Loss From Continuing Operations Before Tax | $-35.80 Million |
Revenues | $0 |
Basic Average Shares | $48.81 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Comprehensive Income/Loss Attributable To Parent | $-35.80 Million |
Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
Other Comprehensive Income/Loss | $-23.84 Million |
Comprehensive Income/Loss | $-35.80 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Prepaid Expenses | $912,000 |
Other Non-current Assets | $664,000 |
Noncurrent Assets | $694,000 |
Equity Attributable To Noncontrolling Interest | $0 |
Current Liabilities | $9.76 Million |
Equity | $-9.13 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Recent Headlines From The Web
Latest news, press releases, and media coverage about APTO from trusted financial sources
Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2025 Financhle. All Rights Reserved.